Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
$0.99
$0.99
$0.99
$0.99
N/A0.25N/AN/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$5.54
$5.55
$2.61
$5.65
$290.24M1.25376,318 shsN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$2.71
+0.6%
$3.06
$1.94
$12.32
$4.06M-0.04125,283 shs25,028 shs
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
$0.00
$0.00
$0.16
$73K-0.0760,924 shsN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
$0.00
$0.00
$0.00
$0.07
N/A2.9821 shs1 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
0.00%0.00%0.00%0.00%0.00%
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00%0.00%0.00%0.00%+0.36%
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
0.00%+2.85%-22.49%+20.22%-57.89%
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
0.00%0.00%0.00%0.00%+200.00%
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
0.00%0.00%0.00%-85.71%-85.71%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
N/AN/AN/AN/AN/AN/AN/AN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
0.00
N/AN/AN/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00
N/AN/AN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
0.00
N/AN/AN/A
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
0.00
N/AN/AN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/AN/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$99.68M2.91N/AN/A$0.88 per share6.30
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
$10.25M0.39N/AN/A$4.74 per share0.57
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
$2.66M0.00N/AN/AN/ANaN
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
$80K0.00N/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/A0.00N/AN/AN/AN/AN/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$5.35M-$2.87N/AN/A-43.80%-101.91%-33.75%8/11/2025 (Estimated)
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
-$33.33MN/A0.00N/AN/AN/AN/AN/AN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
-$1.73MN/A0.00N/AN/AN/AN/AN/A

Latest ALIM, RGRX, EVOK, GNBT, and ADDXF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
-$0.33-$0.51-$0.18-$0.51$3.32 million$3.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/AN/AN/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
N/AN/AN/AN/AN/A
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/AN/AN/AN/AN/A
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
N/AN/AN/AN/AN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
N/AN/AN/A
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
1.80
2.79
2.62
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
N/A
1.55
1.50
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
N/AN/AN/A
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Addex Therapeutics Ltd stock logo
ADDXF
Addex Therapeutics
26N/AN/ANot Optionable
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
15052.39 million35.94 millionOptionable
Evoke Pharma, Inc. stock logo
EVOK
Evoke Pharma
41.49 million1.46 millionNot Optionable
Generex Biotechnology Co. stock logo
GNBT
Generex Biotechnology
15122.06 million79.09 millionNot Optionable
RegeneRx Biopharmaceuticals Inc. stock logo
RGRX
RegeneRx Biopharmaceuticals
31.51 million1.32 millionNot Optionable

Recent News About These Companies

EIGRQ Eiger BioPharmaceuticals, Inc.
The Hawryluk Biopharmaceutical Scholars
Regenerx Biopharmaceuticals Inc RGRXD
Regenerx Biopharm In (RGRXD)
RGRX RegeneRx Biopharmaceuticals, Inc.
RegeneRx To Extend Consent Solicitation Vote
Bristol-Myers to Split Off Mead Johnson

Media Sentiment Over Time

Addex Therapeutics stock logo

Addex Therapeutics OTCMKTS:ADDXF

$0.99 0.00 (0.00%)
As of 02/3/2023

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Alimera Sciences stock logo

Alimera Sciences NASDAQ:ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Evoke Pharma stock logo

Evoke Pharma NASDAQ:EVOK

$2.70 +0.02 (+0.56%)
Closing price 07/3/2025 01:25 PM Eastern
Extended Trading
$2.70 0.00 (-0.18%)
As of 07/3/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Generex Biotechnology stock logo

Generex Biotechnology OTCMKTS:GNBT

Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

RegeneRx Biopharmaceuticals stock logo

RegeneRx Biopharmaceuticals OTCMKTS:RGRX

$0.0002 0.00 (0.00%)
As of 07/3/2025

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation for the treatment of cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for the treatment of dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and HLB Therapeutics. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.